Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor.
de Bruijne J, Bergmann JF, Weegink CJ, van Nieuwkerk CM, de Knegt RJ, Komoda Y, van de Wetering de Rooij JJ, van Vliet A, Jansen PL, Molenkamp R, Schinkel J, Reesink H, Janssen HL. de Bruijne J, et al. Antivir Ther. 2010;15(5):765-73. doi: 10.3851/IMP1606. Antivir Ther. 2010. PMID: 20710058 Clinical Trial.
Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7.
Boonstra A, Liu BS, Groothuismink ZM, Bergmann JF, de Bruijne J, Hotho DM, Hansen BE, van Vliet AA, van de Wetering de Rooij J, Fletcher SP, Bauman LA, Rahimy M, Appleman JR, Freddo JL, Reesink HW, de Knegt RJ, Janssen HL. Boonstra A, et al. Among authors: reesink hw. Antivir Ther. 2012;17(4):657-67. doi: 10.3851/IMP2023. Epub 2011 Dec 19. Antivir Ther. 2012. PMID: 22301364
Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB, Jansen L, de Niet A, Zaaijer HL, Weegink CJ, Terpstra V, Dijkgraaf MG, Molenkamp R, Jansen PL, Koot M, Rijckborst V, Janssen HL, Beld MG, Reesink HW. Takkenberg RB, et al. Among authors: reesink hw. Antivir Ther. 2013;18(7):895-904. doi: 10.3851/IMP2580. Antivir Ther. 2013. PMID: 23639931 Clinical Trial.
HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels.
Jansen L, de Niet A, Stelma F, van Iperen EP, van Dort KA, Plat-Sinnige MJ, Takkenberg RB, Chin DJ, Zwinderman AH, Lopatin U, Kootstra NA, Reesink HW. Jansen L, et al. Among authors: reesink hw. J Hepatol. 2014 Oct;61(4):730-7. doi: 10.1016/j.jhep.2014.05.004. Epub 2014 May 10. J Hepatol. 2014. PMID: 24824278
Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F, de Niet A, Tempelmans Plat-Sinnige MJ, Jansen L, Takkenberg RB, Reesink HW, Kootstra NA, van Leeuwen EM. Stelma F, et al. Among authors: reesink hw. J Infect Dis. 2015 Oct 1;212(7):1042-51. doi: 10.1093/infdis/jiv180. Epub 2015 Mar 19. J Infect Dis. 2015. PMID: 25791117
353 results